Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28577921 | 0.94 | HPGD (0.49) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL29215696 | 0.90 | HPGD (0.48) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL30342278 | 0.90 | HPGD (0.48) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL408862 | 0.84 | HPGD (0.58) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL25173198 | 0.83 | HPGD (0.51) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL22648878 | 0.83 | HPGD (0.51) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL18285469 | 0.83 | EPHX1 (0.52) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL31735264 | 0.82 | NR1H2 (0.50) | HPGDGPR119RECQLEPHX1MAPT | |
| SCHEMBL32671892 | 0.82 | HPGD (0.57) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL31111836 | 0.82 | HPGD (0.50) | HPGDGPR119RECQLEPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20240390383-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-11-28 | — | — | US | disclosed |
| CN-118076599-A | Dioxazines and their use in the treatment of GBA related diseases | 泽拉丹麦有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-110392678-B | Compounds and methods for IDO and TDO modulation, and indications therefor | 普莱希科公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3768666-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112119072-A | Compounds and methods for IDO and TDO modulation, and indications thereof | 普莱希科公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-10-03 | — | — | US | disclosed |
| WO-2019183145-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3515892-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | HPGD 2940/4885GPR119 161/4885RECQL 531/4885 |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | IDO1, TDO2, IDO2 | HPGD 326/4885GPR119 86/4885RECQL 1479/4885 |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | HPGD 250/4885GPR119 229/4885RECQL 958/4885 |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | HPGD 326/4885GPR119 86/4885RECQL 1479/4885 |
| US-20240390383-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | GBA1, GBA2, GBA3 | HPGD 2007/4885GPR119 16/4885RECQL 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.